JPWO2020138085A1 - 疾患予測システム - Google Patents
疾患予測システム Download PDFInfo
- Publication number
- JPWO2020138085A1 JPWO2020138085A1 JP2020563306A JP2020563306A JPWO2020138085A1 JP WO2020138085 A1 JPWO2020138085 A1 JP WO2020138085A1 JP 2020563306 A JP2020563306 A JP 2020563306A JP 2020563306 A JP2020563306 A JP 2020563306A JP WO2020138085 A1 JPWO2020138085 A1 JP WO2020138085A1
- Authority
- JP
- Japan
- Prior art keywords
- information
- disease
- input
- prediction
- prediction system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 86
- 230000003054 hormonal effect Effects 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 12
- 210000002700 urine Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000013528 artificial neural network Methods 0.000 description 25
- 208000001132 Osteoporosis Diseases 0.000 description 22
- 210000000988 bone and bone Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 239000002661 non steroidal estrogen Substances 0.000 description 9
- 230000004097 bone metabolism Effects 0.000 description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 201000001881 impotence Diseases 0.000 description 6
- 238000012417 linear regression Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 208000001076 sarcopenia Diseases 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 238000010897 surface acoustic wave method Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 208000036119 Frailty Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000013527 convolutional neural network Methods 0.000 description 4
- 238000010801 machine learning Methods 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 3
- 238000013473 artificial intelligence Methods 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 3
- 229960001348 estriol Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 208000005801 spondylosis Diseases 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 description 2
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 102000019307 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/02—Analysing fluids
- G01N29/022—Fluid sensors based on microsensors, e.g. quartz crystal-microbalance [QCM], surface acoustic wave [SAW] devices, tuning forks, cantilevers, flexural plate wave [FPW] devices
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Theoretical Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Acoustics & Sound (AREA)
- Artificial Intelligence (AREA)
- Biophysics (AREA)
- Computational Linguistics (AREA)
- Evolutionary Computation (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Mathematical Physics (AREA)
- Software Systems (AREA)
- Endocrinology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
入力情報Iは、前記疾患の診断に使用される対象者の第1情報I1を有している。第1情報I1は、例えば対象者の検査結果や医用画像であればよい。具体的には、例えば疾患予測システム1が骨粗しょう症を予測する場合には、対象者の骨量、骨代謝マーカー、胸部、腰部もしくは大腿骨近位部のレントゲン画像、CT像などであればよい。
予測部32は、入力情報Iから予測結果Oを算出可能なように、学習用データと教師用データを用いた機械学習によって最適化される。すなわち、制御部34は、機械学習によって最適化された近似式(予測部32)に基づいて入力情報Iから予測結果Oを算出するが、入力部31に入力された学習用データから演算されて出力部33から出力された疑似予測結果と教師用データとの差が小さくなるように、予測部32内のパラメータを調整することによって、機械学習される。その結果、予測部32は、入力情報Iに対して学習済みパラメータに基づく演算を行なって予測結果Oを出力することができる。
図5は、本開示の線形回帰モデルを用いた予測部32aの構成の概念を示す。
2 端末装置
21 第1端末装置
22 第2端末装置
3 予測装置
31 入力部
32 予測部
32a 予測部
32b 予測部
33 出力部
34 制御部
35 記憶部
O 予測結果
I 入力情報
Claims (9)
- 疾患の診断に使用される対象者の第1情報および前記対象者のホルモン様作用物質に関する第2情報を有した入力情報が入力される入力部と、
前記入力部に入力された前記入力情報から前記対象者の将来の前記疾患の発症を予測する制御部と、を備える、疾患予測システム。 - 請求項1に記載の疾患予測システムであって、
前記制御部が予測した予測結果を出力する出力部をさらに備える、疾患予測システム。 - 請求項1または2のいずれかに記載の疾患予測システムであって、
前記疾患のうち2種類以上を同時に予測する、疾患予測システム。 - 請求項1〜3のいずれかに記載の疾患予測システムであって、
前記第2情報は、対象者の血中または尿中のホルモン様作用物質の測定値を含む、疾患予測システム。 - 請求項1〜4のいずれかに記載の疾患予測システムであって、
前記予測は経年的に予測される、疾患予測システム。 - 請求項1〜5のいずれかに記載の疾患予測システムであって、
前記入力情報は、前記被検者の健康状態に関する第3情報を含む、疾患予測システム。 - 請求項1〜6のいずれかに記載の疾患予測システムあって、
前記入力情報は、前記被検者への介入に関する第4情報を含む、疾患予測システム。 - 請求項1〜7のいずれかに記載の疾患予測システムであって、
前記制御部は、前記第4情報を除く入力情報に基づく第1結果と、前記第4情報を含む入力情報に基づく第2結果と、を予測する、疾患予測システム。 - 制御部、入力部および出力部を備えている疾患予測システムにより実行されるプログラムであって、
前記プログラムは、前記制御部に、
前記入力部を介して、疾患の診断に使用される対象者の第1情報および前記対象者のホルモン様作用物質に関する第2情報を有した入力情報を取得する取得ステップと、
前記入力情報から前記対象者の将来の前記疾患の発症を予測する予測ステップと、
前記制御部が予測した予測結果を出力する出力ステップと、を実行させるプログラム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023106415A JP2023121815A (ja) | 2018-12-25 | 2023-06-28 | 疾患予測システム |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018241064 | 2018-12-25 | ||
JP2018241064 | 2018-12-25 | ||
PCT/JP2019/050611 WO2020138085A1 (ja) | 2018-12-25 | 2019-12-24 | 疾患予測システム |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023106415A Division JP2023121815A (ja) | 2018-12-25 | 2023-06-28 | 疾患予測システム |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2020138085A1 true JPWO2020138085A1 (ja) | 2021-11-11 |
Family
ID=71126433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020563306A Pending JPWO2020138085A1 (ja) | 2018-12-25 | 2019-12-24 | 疾患予測システム |
JP2023106415A Pending JP2023121815A (ja) | 2018-12-25 | 2023-06-28 | 疾患予測システム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023106415A Pending JP2023121815A (ja) | 2018-12-25 | 2023-06-28 | 疾患予測システム |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220082574A1 (ja) |
EP (1) | EP3903666A4 (ja) |
JP (2) | JPWO2020138085A1 (ja) |
WO (1) | WO2020138085A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6830298B1 (ja) * | 2020-04-30 | 2021-02-17 | 株式会社Jdsc | 情報処理システム、情報処理装置、情報処理方法、及びプログラム |
US11076824B1 (en) * | 2020-08-07 | 2021-08-03 | Shenzhen Keya Medical Technology Corporation | Method and system for diagnosis of COVID-19 using artificial intelligence |
JPWO2022158490A1 (ja) * | 2021-01-20 | 2022-07-28 | ||
JPWO2022190891A1 (ja) * | 2021-03-11 | 2022-09-15 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007092433A2 (en) * | 2006-02-06 | 2007-08-16 | Tethys Bioscience, Inc. | Osteoporosis associated markers and methods of use thereof |
JP2011508228A (ja) * | 2007-12-28 | 2011-03-10 | エフ.ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
JP2018005726A (ja) * | 2016-07-06 | 2018-01-11 | オムロンヘルスケア株式会社 | リスク分析システム及びリスク分析方法 |
JP2018044877A (ja) * | 2016-09-15 | 2018-03-22 | 学校法人慶應義塾 | 被験者における骨密度低下の発症又は進行を予測する方法 |
JP2018124702A (ja) * | 2017-01-31 | 2018-08-09 | 株式会社教育ソフトウェア | 病因分析装置および疾病予測装置 |
US20180247020A1 (en) * | 2017-02-24 | 2018-08-30 | Siemens Healthcare Gmbh | Personalized Assessment of Bone Health |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008036068A (ja) | 2006-08-04 | 2008-02-21 | Hiroshima Univ | 骨粗鬆症診断支援装置および方法、骨粗鬆症診断支援プログラム、骨粗鬆症診断支援プログラムを記録したコンピュータ読み取り可能な記録媒体、骨粗鬆症診断支援用lsi |
-
2019
- 2019-12-24 US US17/418,174 patent/US20220082574A1/en active Pending
- 2019-12-24 EP EP19905160.8A patent/EP3903666A4/en active Pending
- 2019-12-24 WO PCT/JP2019/050611 patent/WO2020138085A1/ja unknown
- 2019-12-24 JP JP2020563306A patent/JPWO2020138085A1/ja active Pending
-
2023
- 2023-06-28 JP JP2023106415A patent/JP2023121815A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007092433A2 (en) * | 2006-02-06 | 2007-08-16 | Tethys Bioscience, Inc. | Osteoporosis associated markers and methods of use thereof |
JP2011508228A (ja) * | 2007-12-28 | 2011-03-10 | エフ.ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
JP2018005726A (ja) * | 2016-07-06 | 2018-01-11 | オムロンヘルスケア株式会社 | リスク分析システム及びリスク分析方法 |
JP2018044877A (ja) * | 2016-09-15 | 2018-03-22 | 学校法人慶應義塾 | 被験者における骨密度低下の発症又は進行を予測する方法 |
JP2018124702A (ja) * | 2017-01-31 | 2018-08-09 | 株式会社教育ソフトウェア | 病因分析装置および疾病予測装置 |
US20180247020A1 (en) * | 2017-02-24 | 2018-08-30 | Siemens Healthcare Gmbh | Personalized Assessment of Bone Health |
Also Published As
Publication number | Publication date |
---|---|
EP3903666A1 (en) | 2021-11-03 |
JP2023121815A (ja) | 2023-08-31 |
WO2020138085A1 (ja) | 2020-07-02 |
US20220082574A1 (en) | 2022-03-17 |
EP3903666A4 (en) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7283672B1 (ja) | 学習モデル生成方法、プログラム、記録媒体及び装置 | |
JPWO2020138085A1 (ja) | 疾患予測システム | |
JP2019200788A (ja) | 将来の骨量を予測する方法、情報処理装置、及びコンピュータプログラム | |
Eleazer | The interaction of mechanical loading and metabolic stress on human cortical bone: Testing anthropological assumptions using cross-sectional geometry and histomorphology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230328 |